Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 13;8(24):39782-39794.
doi: 10.18632/oncotarget.16349.

Chemoradiotherapy enhanced the efficacy of radiotherapy in nasopharyngeal carcinoma patients: a network meta-analysis

Affiliations
Review

Chemoradiotherapy enhanced the efficacy of radiotherapy in nasopharyngeal carcinoma patients: a network meta-analysis

Jian He et al. Oncotarget. .

Abstract

Object: A Bayesian network meta-analysis (NMA) was conducted to estimate the overall survival (OS) and complete response (CR) performance in nasopharyngeal carcinoma (NPC) patients who have been given the treatment of radiotherapy, concurrent chemoradiotherapy (C), adjuvant chemotherapy (A), neoadjuvant chemotherapy (N), concurrent chemoradiotherapy with adjuvant chemotherapy (C+A), concurrent chemoradiotherapy with neoadjuvant chemotherapy (C+N) and neoadjuvant chemotherapy with adjuvant chemotherapy (N+A).

Methods: Literature search was conducted in electronic databases. Hazard ratios (HRs) accompanied their 95% confidence intervals (95%CIs) or 95% credible intervals (95%CrIs) were applied to measure the relative survival benefit between two comparators. Meanwhile odd ratios (ORs) with their 95% CIs or CrIs were given to present CR data from individual studies.

Results: Totally 52 qualified studies with 10,081 patients were included in this NMA. In conventional meta-analysis (MA), patients with N+C exhibited an average increase of 9% in the 3-year OS in relation to those with C+A. As for the NMA results, five therapies were associated with a significantly reduced HR when compared with the control group when concerning 5-year OS. C, C+A and N+A also presented a decreased HR compared with A. There was continuity among 1-year, 3-year and 5-year OS status. Cluster analysis suggested that the three chemoradiotherapy appeared to be divided into the most compete group which is located in the upper right corner of the cluster plot.

Conclusion: In view of survival rate and complete response, the NMA results revealed that C, C+A and C+N showed excellent efficacy. As a result, these 3 therapies were supposed to be considered as the first-line treatment according to this NMA.

Keywords: chemoradiotherapy; complete response; nasopharyngeal carcinoma; network meta-analysis; overall survival.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTERESTS

All authors declare no compete interests.

Figures

Figure 1
Figure 1. Flow chart of study selection
Figure 2
Figure 2. The network plot of included interventions
Figure 3
Figure 3. Clustered ranking plot of the network
The plot is based on cluster analysis of surface under the cumulative ranking curves (SUCRA) values. Each plot shows SUCRA values for two outcomes. Each color represents a group of treatments that belong to the same cluster. Treatments lying in the upper right corner are more effective and safe than the other treatments.
Figure 4
Figure 4. Net heat plot
Warm color in the net heat plot indicates that significant inconsistency may arise from a specific design or comparison and this trend is illustrated by the intensity of the color.

Similar articles

Cited by

References

    1. Liang R, Shen X, Chen ZH, Yu ZH. Radiosensitization of CMNa of Locally Recurrent Nasopharyngeal Cancer. Tumor Prevention and Treatment. 2008;21:162–164.
    1. Liao SH. CMNa on clinical effect of nasopharyngeal carcinoma radiotherapy sensitization. Guangxi Medical Journal. 2008;30:27–28.
    1. Liu SB, Li M, Pan YF, Liang BH. Clinical study of CMNa combined with radiotherapy on advanced nasopharyngeal carcinoma. Modern Oncology. 2010;18:2137–2138.
    1. Ma HM, Yuan X, Huang YL, Lin YF, Liu CX. Paclitaxel and cisplatin, 5 -fluorouracil (TPF) programme neoadjuvant chemotherapy for advanced nasopharyngeal cancer. Modern Oncology. 2009;17:1233–1235.
    1. Tan JM, Li MY, Lin DR. Radiosensitization of Sodium Glycididazole in re-radiotherapy for local current nasopharyngeal carcinoma. Modern Medicine Journal of China. 2008;10:25–27.